• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

UArizona Cancer Center researchers develop new way to target cancer cells

Bioengineer by Bioengineer
September 25, 2023
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers from the University of Arizona Cancer Center have identified a new method of activating specific molecules to target cancer cells while leaving healthy cells unharmed.

Wei Wang

Credit: UArizona Health Sciences

Researchers from the University of Arizona Cancer Center have identified a new method of activating specific molecules to target cancer cells while leaving healthy cells unharmed.

In their recent study, published in the Journal of the American Chemical Society, Wei Wang, PhD, and his team developed a new strategy called click-release proteolysis targeting chimeras, or crPROTACs, that allows for the activation and release of PROTACs only in cancer cells.

“The studies open a new way to deliver anti-cancer drugs to cancer cells,” Wang said. “We are exploring the technology for the treatment of more challenging senescent cancer cells and other diseases.”

PROTACs are molecules that scientists designed to break down specific proteins in the body. They are now explored as a potential treatment for cancer; however, one of the challenges is that they can be harmful to healthy cells due to uncontrolled protein breakdown. 

Wang’s research focuses on an existing metabolic pathway in the human system, the ubiquitin-proteasome pathway, that normally targets proteins for degradation and recycling. Wang’s strategy uses the pathway to specifically target cells at tumor sites, minimizing premature drug activation and unwanted side effects. The researchers found that the crPROTAC strategy successfully degraded proteins of interest in cancer cells. 

“Unlike many other drug delivery strategies, this approach will be very precise in targeting just the tumor,” Wang said.

Wang’s approach stems from biorthogonal and click chemistry, which was originally developed by Carolyn Bertozzi, MS, PhD, for which she won the Nobel Prize in chemistry in 2022.

Wang is a professor at the R. Ken Coit College of Pharmacy’s Department of Pharmacology and Toxicology, co-director of Arizona Center for Drug Discovery, and member of the BIO5 Institute and UArizona Cancer Center. He recently received the inaugural UArizona Cancer Center Research Award for Basic Science for this research and publication.

Wang’s research team from the Wang Lab in the Coit College of Pharmacy included graduate students Mengyang Chang and Devin Pontigon; postdoctoral scholars Feng Gao, PhD, and Giri Gnawali, PhD; and postdoctoral research associate Hang Xu, PhD



Journal

JACS

DOI

10.1021/jacs.3c05159

Subject of Research

Cells

Article Title

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Article Publication Date

16-Jun-2023

COI Statement

The authors declare no competing financial interest.

Share12Tweet8Share2ShareShareShare2

Related Posts

Whole Exome Sequencing Links FANCM to ER-Negative Breast Cancer

Whole Exome Sequencing Links FANCM to ER-Negative Breast Cancer

August 21, 2025
blank

Adipocyte IL6 and Cancer CXCL1 Drive STAT3/NF-κB Crosstalk

August 21, 2025

Key Traits That Predict Disease Emergence in New Populations

August 21, 2025

STN1 Drives Pancreatic Cancer Metastasis via ZEB1

August 21, 2025

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Atomically Thin Material Wrinkles Pave the Way for Ultra-Efficient Electronics

How Cells Manage Stress: New Study Uncovers the Role of Waste Disposal Systems in Overinflated Balloons

Whole Exome Sequencing Links FANCM to ER-Negative Breast Cancer

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.